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Abstract 
Background: Chronic kidney disease (CKD) is an established risk factor for cardiovascular 
disease, but the significance of lower Glomerular filtration rate on incidence and mortality from 
cancer is uncertain. There is evidence that cancer risk and cancer mortality may be increased in 
individuals with End Stage Renal Disease (ESRD) requiring dialysis or after renal transplantation 
but whether less severe kidney disease is associated with cancer remains poorly understood.  
Some studies indicate that these associations do appear to be organ specific. It has been reported 
that reduced renal function is associated with an increased risk of cancers of the kidney and Genito-
urinary system, gastrointestinal, lung and some soft tissue and hematological cancers like 
myeloma. 
Objectives: To characterize the Chronic Kidney Disease (CKD) patients by cancer incidents. 
Additionally, to calculate the crude and age-adjusted cancer incidence in individuals with 
compromised kidney function.  
Methods: A retrospective cohort study was conducted using the electronic medical record 
information from the patients received treatment at Nebraska Medicine from 2008 to 2018, 
extracted by UNMC Public Health Informatics lab. The subjects with Chronic Kidney Disease and 
eventually advanced to cancer were included in the study (N=869). The subjects are characterized 
by descriptive comparison of age, gender, race, most frequent medical conditions, body mass 
index, smoking status, and frequently diagnosed cancer.  
Results: The cohort is predominant with Caucasian (n=702; 80.78%) male (n=486; 55.93%) 
population with median age 71 (IQR: 63.53). Major proportion of the individuals in the cohort are 
obese (n=283; 32.57%). The frequent cancer types among the cohort are digestive (n=129; 
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14.85%), urinary (n=105; 12.08%), respiratory (n=96; 11.05%), skin (n=95; 10.93%) and leukemia 
(n=90; 10.36%). The crude/age-adjusted incidence of the frequently observed cancer groups was 
exponentially higher than the national, state and the city estimates.  
 
Introduction 
Placement site 
The Big Data to Knowledge (BD2K) lab, is a part of the UNMC Division of Public Health 
Informatics, located at DRC II. Nebraska Medical Center. The research at Big Data to Knowledge 
Lab mainly focused on mining patient information from clinical practice, rendering information 
into machine-readable formats and analyzing the data using computational techniques to support 
clinical care, population health, and analytics. The key focus areas are extracting clinical 
information involves capturing information generated from the interaction between the patient and 
the healthcare team. Capturing clinical information in a machine-readable format, using SNOMED 
CT, RxNORM, and LOINC. Developing machine learning algorithms to generate evidence-based 
insights that benefit clinical practice and population health. In response to the patient-centered 
outcome research initiative to provide timely answers to the research questions to draw beneficial 
health outcomes, the BD2K lab developed clinical data models that retrieve relevant information 
from Electronic Health Records.  
Problem Statement 
There are no evidence-based cancer screening recommendations tailored for patients with Chronic 
Kidney Disease. If estimated Glomerular Filtration Rate is associated with an increased risk of 
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certain organ-specific cancers, then could this have implications for directing cancer screening 
efforts in this select population with Chronic Kidney Disease. 
Importance of the project to the organization/clinical community 
The capstone activity is a collaboration between Nebraska Medicine and UNMC, wherein the 
clinical aspects of the project are initiated by Dr. Apar Ganti (Oncologist) and Dr. Ketki Tendulkar 
(Nephrologist), noticed a significant number of patients with compromised renal function are being 
diagnosed with cancer over time. So, characterizing and identifying the risks could directly impact 
the clinical care of Chronic Kidney Disease patients regarding the frequency and method of cancer 
screening aids early detection of cancer. 
Purpose and Rationale of the Study:  
 Majority of the epidemiologic studies are based on the national/state cancer surveillance 
database, wherein the information is data rich to calculate the incidence and mortality for specific 
cancer type. The cancer surveillance databases often fail to provide patient-related clinical 
information. Therefore, the proposed study is utilizing the i2b2 database that contains all the 
clinical data that is recorded in the patient’s electronic health record. This includes patient disease 
history, medication history, diagnostic test results (histopathology, imaging, genetic tests, organ-
specific diagnostic profiles) ever conducted during the patient encounter. 
 The study fills the gaps/possible confounders while evaluating the epidemiologic 
association between cancer and Chronic Kidney Disease.    
Goals and Objectives: 
Aim: To characterize chronic kidney disease (CKD) patient population with different cancer types 
at Nebraska Medicine, Omaha, NE, from 2008 to 2018. 
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Hypothesis 
We hypothesize that there is an increased risk of cancer incidence associated with renal impairment 
(dialysis dependent and patients with glomerular filtration rate less than 60 ml/min/1.73 m3).  
Literature review 
The patients with renal failure are at higher risk to develop cancer and with higher cancer mortality 
rate than compared to individuals with optimum kidney function. Multiple population-based 
studies conducted to analyze the association between impaired kidney function and cancer have 
reported an increased risk associated with thyroid/endocrine, gastrointestinal, hepatobiliary, 
urinary tract, kidney cancer and for multiple myeloma and chronic myeloid leukemia.  
The incidence pattern across different countries varied, a cohort from Taiwan showed a higher 
incidence of bladder cancer (SIR 8.2 95% CI 6.7-9.9) (Lin et al., 2012) and lung cancer compared 
to kidney cancer (HR 8.81 95% CI 6.62-11.72) (Chien et al., 2017). Additionally, Kidney cancer 
is higher in the United States for both dialysis-dependent patients (OR 2.42 95% CI 2.01-2.92) 
(Shebl, Warren, Eggers, & Engels, 2012) and patients with glomerular filtrate rate less than 60 
(Christensson et al., 2013; Lowrance, Ordonez, Udaltsova, Russo, & Go, 2014), Australia and New 
Zealand (SIR 9.9 95% CI 7.7-12.3) and Europe (SIR 3.3 95% CI 3.1-3.6) (Maisonneuve et al., 
1999). The cohort from Korea showed a higher incidence of urinary tract cancer (SIR 4.7 95% CI 
2.42-8.19) (Yoo et al., 2017).  
A study based on white Australian cohort identified that risk of cancer death increases by 29% 
(mean follow up 10.1 years) and 18% (mean follow up period 12.8 years) for every 10 ml/min/1.73 
m3 reduction in estimated Glomerular Filtration Rate, with higher risk associated with lung, breast 
and urinary tract cancer deaths among patients with reduced kidney function (Iff et al., 2014; Wong 
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et al., 2009). The overall risk assessment of cancer associated with renal impairment remained 
inconsistent among literature and geographical locations.  
The underlying factor for this observation could be due to genomic instability and genetic damage 
in Chronic Kidney Disease patients possibly due to the accumulation of uremic toxins, oxidative 
stress mediators and endogenous substances with genotoxic properties. Observation of DNA 
damage assessed by comet assay show higher DNA damage in Chronic Kidney Disease patients 
(21.42 ± 0.41 %) than controls (7.74 ± 0.41%) (Corredor et al., 2015). Other assays such as alkaline 
comet assay and cytokine block micronucleus assay in peripheral blood lymphocytes have also 
been used to quantify the DNA and chromosomal damage, and conclude that there is a significant 
increase in micronucleus frequency and tail DNA intensity in Chronic Kidney Disease patients 
(Rangel-Lopez et al., 2013).  
A study based on pediatric population, used comet/enzyme-modified comet assay to determine the 
percentage DNA intensity as a measure of genetic damage found and oxidative DNA damage in 
formamidopyrimidine DNA glycosylase, is significantly higher in a pediatric group with Chronic 
Kidney Disease (Aykanat et al., 2011). A comet assay of biomarkers of DNA damage including 
micronuclei, DNA strand breaks found to be higher in Chronic Kidney Disease patients 
undergoing dialysis (Schupp, Stopper, & Heidland, 2016). 
There is a definitive relationship between kidney function and cancer, in terms of both biological 
assays and population-based studies that demonstrated statistically significant correlations. 
However, the cancer types across geographical regions varied remarkably. 
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Methods 
Research question: 
Do patients with chronic kidney disease patients have an increased risk of developing cancer? 
Study Design  
A single-center retrospective population-based cohort study that includes patients 
diagnosed/treated for Chronic Kidney Disease prior to cancer diagnosis, at Nebraska Medicine 
from 2008 to 2018.  
Study Population/Study sample/Data sources/ Data collection methods 
The cohort predominantly includes Nebraska residents with Chronic Kidney Disease prior to 
cancer diagnosis and treated at Nebraska Medicine. For this study, de-identified patient 
information retrieved from i2b2, through the BD2K lab maintained by Dr. W. Scott Campbell 
M.B.A., Ph.D. 
The information retrieved from i2b2 is rich in clinical information as the data is exchanged directly 
from the patient’s electronic health record. The probability of data errors is expected to be 
decidedly less, as the automated machine algorithms segregate the information from the electronic 
health record and involve minimal or no manual data entry during the data exchange.  
The de-identified data contain multiple files with a pseudo-patient identification number (primary 
key), that is mapped to eGFR test results, clinical diagnoses (SNOMED CT concept codes), body 
mass index ever documented for the patient at Nebraska Medicine, date of birth, gender and race. 
This allowed me to develop an entity relationship scheme (by one to many or many to one relation) 
using MySQL Workbench (Ver. 8.0.12) and Tableau Prep (Ver. 2018.2).  
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Systematized Nomenclature of Medicine – Clinical Terms (SNOMED CT) Design: 
The SNOMED CT is maintained by the International Health Terminology Standard 
Development 
Organization 
(IHTSDO). 
Unlike the 
International 
Classification 
of Diseases, 
SNOMED 
captures 
granular clinical Fig 2. SNOMED CT hierarchy design 
Fig 1. Extraction of analytic dataset 
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information from electronic health records. Allows medical practitioners to capture detailed 
ontologies and catalog the patient clinical problem list (Bhattacharyya, 2015; SNOMED, 2014).  
In the current study, I 
included all the 
concept codes related 
to Chronic kidney 
disease and cancers. 
The SNOMED CT 
contains about 58 
different classifications of 
the parent diagnosis ‘Chronic Kidney Disease’ (SNOMED, 2014). 
Additionally, SNOMED CT code descriptions are extracted using Python (Python Version 2.7.14) 
Application Programming Interface (API) based on SNOMED English version 20180131 
developed by SNOMED international. 
Source code (Apache license Ver. 2.0, Jan 2004): 
from urllib.request import urlopen 
from urllib.parse import quote 
import json 
 
baseUrl = 'http://browser.ihtsdotools.org/api/v1/snomed/' 
edition = 'en-edition' 
version = 'v20180131' 
#Prints description of a concept ID 
 
def getConceptById(id): 
    url = baseUrl + edition + '/' + version + '/concepts/' + id 
    response = urlopen(url).read() 
    data = json.loads(response.decode('utf-8')) 
Fig 3. Chronic Kidney Disease schematic representation 
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    print (data['fsn']) 
getConceptById('XXXXXXXXXX') 
 
Eligibility criterion 
Inclusion 
• Subjects with chronic kidney disease and eventually developed cancer. 
• Age of 18 and above, received care at Nebraska Medicine between 2008 and 2018 
• Subjects with at least three estimated Glomerular Filtration Rate results available in a year 
before cancer diagnosis.  
Exclusion 
• All the subjects diagnosed with secondary and metastatic cancer were excluded. 
• All the individuals underwent a kidney transplant before the date of cancer diagnosis are 
excluded. 
Case Ascertainment 
The i2b2 database contains detailed de-identified patient information who are treated at Nebraska 
Medicine.  
Measurement of Outcomes 
Primary outcome: The primary outcome is to characterize the cohort by age, gender, race by cancer 
type and eGFR group. 
Abstracted Variables 
Age, gender, race, the clinical information includes co-morbidities, month and year of Chronic 
Kidney Disease/cancer diagnosis, cancer type, glomerular filtration rate.  
 
Statistical Methods  
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The subjects are classified into four estimated Glomerular Filtration Rate groups based on the 
average of the latest three eGFR estimate results based on individual patient’s cancer diagnosis 
date.  
The eGFR grouping is based on Kidney Disease Improving Global Outcomes (KDIGO) 2012 
classification and due to smaller sample size, the KIDGO classification is slightly modified 
(Bargman & Skorecki, 2018).  
The cancer related SnomedCT concept code descriptions are mapped to International 
Classification of Disease for Oncology Version 3.0 Topographical codes and the patients are 
grouped by primary site of cancer (International Classification of Diseases for Oncology, 2013). 
The crude and age-adjusted incidence are calculated for the chronic kidney disease population who 
received treatment from Nebraska Medicine. The population proportions for respective age groups 
were extracted from US Census Bureau - 2010 Decennial estimates for Omaha (2010 Census 
Summary File 1, 2012). Additionally, the age-adjusted incidence is compared with the US, 
Nebraska and Omaha-Council Bluffs region. The age-adjusted cancer incidence for US, Nebraska 
and Omaha-Council Bluffs was extracted from CDC Wonder – cancer incidence database for the 
year 2006 – 2015 including the population of age 20 years and older for comparison (Control & 
Prevention, 2008). 
The descriptive statistics for the variables age, gender, ethnicity, medical history, body mass index, 
smoking history by cancer groups and estimated Glomerular Filtration Rate groups are generated 
using SAS software, version 9.4 ("SAS 9.4," 2012). The descriptive statistics and comparison of 
proportions for categorical data using Chi-Square or Fisher Exact test, categorical and continuous 
data using Kruskal-Wallis test (Burlew, 2005; Cody, 2011). 
Results 
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A total of 869 subjects are enrolled in the study: 468 male and 383 females with a median age of 
71 years (IQR 63.53, 79.52). The subjects are all chronic kidney disease patients who developed 
cancer and received patient care at Nebraska Medicine from the year 2008 to 2018. 
The cohort is 
predominant with male 
(55.93%) Caucasians 
(80.78%) with a median 
age of 71 years (IQR 
63.53, 79.52). The 
median estimated 
Glomerular filtration rate 
is 51 ml/min/ 1.73 m3 
(IQR 37.66, 60) and 
majority (36.48%) of the 
individuals within 
estimated glomerular 
filtration rate between 45 
to 50 ml/min/1.73 m3, 
which is clinically 
considered as mild to moderately decreased kidney function according to the Kidney Disease 
Improving Global Outcome (KDIGO) classification of chronic kidney disease (Bargman & 
Skorecki, 2018). 
Classification Frequency Percent At risk Crude 
All cancer cases 869  20400 4259.80 
Digestive system 129 14.84 20400 632.35 
Urinary system 105 12.08 20400 514.71 
Respiratory system 96 11.05 20400 470.59 
Skin 95 10.93 20400 465.69 
Leukemia 90 10.36 20400 441.18 
Male genital system 87 10.01 11240 774.02 
Breast 66 7.59 20400 323.53 
Neoplasm, uncertain whether 
benign or malignant 
46 5.29 20400 225.49 
Sarcoma, NOS 38 4.37 20400 186.27 
Female genital system 30 3.45 9160 327.51 
Malignant neoplasms of ill-
defined, other secondary and 
unspecified sites 
21 2.42 20400 102.94 
Oral cavity and Pharynx 18 2.07 20400 88.24 
Neuroendocrine carcinoma, 
NOS 
11 1.27 20400 53.92 
Carcinoma in situ, NOS 10 1.15 20400 49.02 
Endocrine system 10 1.15 20400 49.02 
Malignant Neoplasm of 
Genitourinary Organs 
9 1.04 20400 44.12 
Bone and joint 4 0.46 20400 19.61 
Brain and other nervous 
system 
2 0.23 20400 9.80 
Mesothelioma and soft tissue 2 0.23 20400 9.80 
Table 1. Crude cancer incidence per 100,000 
14 
 
The most frequent cancer among the cohort are digestive (14.85%), urinary (12.08%), respiratory 
(11.05%), skin (10.93%) and leukemia (10.36%). More than half (51.32%) of the subjects in the 
cohort developed cancer within a year from clinical diagnosis of chronic kidney disease. The 
median time to develop cancer in the cohort is 45 weeks (IQR 3.85, 175.28) post clinical diagnosis 
of chronic kidney disease.  
 
The overall crude and age-adjusted cancer incidence among chronic kidney disease patients are 
exponentially high compared to the country (US), state (Nebraska) and city (Omaha / Council-
Bluffs region). The overall cancer incidence in chronic kidney disease patients is about five times 
higher than the national average with an incidence rate of 3406.97 per 100,000 population.  
The incidence of digestive cancer in chronic kidney disease patients is 3 times higher (415.67 per 
100,000 population), urinary system cancers are 23 times higher (415.58 per 100,000 population), 
respiratory cancer 3 times (314.06 per 100,000 population), skin cancers 13 times higher (422.71 
per 100,000) and leukemia 23 times higher (412.58 per 100,000 population) than the US national 
average.  
 
  
Standard 
Population 
Age 
distribution 
of a standard 
population 
Cohort 
population 
cancer 
Digestive 
System 
Urinary 
System 
Respiratory 
System 
Skin 
cancer 
Leukemia 
Age 
group 
                  
18 - 59 240074 0.783820404 5108 2286.40 245.52 322.24 214.83 306.90 306.90 
60 - 69 33177 0.108319974 4192 625.32 87.85 77.52 67.18 62.02 51.68 
70 - 79 18947 0.061860281 4933 342.34 57.68 36.37 42.64 38.87 33.86 
80+ 14089 0.04599934 6167 152.91 24.61 18.65 16.41 14.92 20.14 
Total 306287 1 20400 3406.97 415.67 454.78 341.06 422.71 412.58 
  
Standard population estimates retrieved from US Census Bureau 2010 Decennial census for Omaha 
Table 2. Age-adjusted cancer incidence per 100,000 
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About 40 % of the of the cancer types include male genital (n=87; 10.01%), breast (n=66; 7.59%), 
neoplasms (uncertain whether benign or malignant) (n=46; 5.29%), sarcoma (n=38; 4.37%), 
female genital (n=30; 3.45%), malignant neoplasms (n=21; 2.42%), oral cavity/pharynx (n=18; 
2.07%), neuroendocrine carcinoma (n=11; 1.27%), carcinoma in-situ (n=10; 1.15%), endocrine 
n=10; 1.15%), malignant neoplasm of genitourinary tract (n=9; 1.04%), bone/joint (n=4; 0.46%), 
brain/other nervous system and mesothelioma/soft tissue with 2 (0.23%) cases in each category. 
All the subjects in the cohort are with at least one or more active clinical diagnosis of chronic 
disease. The most frequent chronic disease conditions among the cohort are anemia (44.99%), 
depression (22.78%), diabetes (38.09%), gastroesophageal reflux disease (GERD) (27.85%), heart 
failure (24.84%), hypertension (82.28%) and hyperlipidemia (46.49%).  
 
Fig 4. Age-adjusted incidence comparison 
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Major proportion of the individuals in the cohort are in age group of 70 to 79 years (n=273; 
31.42%) and 60 to 69 years (n=242; 27.85%), but age distribution do not have statistical 
differences among different cancer groups (chi-square = 22.6654, df=21, P=0.3621). Even the 
median age among cancer groups is not statistically different (Kruskal Wallis = 4.3668, df=7, 
P=0.7367). In contrast, the frequency of subjects in terms of gender and ethnicity are statistically 
different among cancer groups. The gender being male has higher number of cancers: digestive 
(n=69; 7.94%), urinary (n=75; 8.63%), respiratory (n=47; 5.41%), skin cancer (n=60; 6.9%) and 
leukemia (n=61; 7.02) (chi-square = 13.6324, df=7, P<0.0001). The distribution of cancer patients 
across different ethnic groups has statistical differences, wherein whites with higher proportion 
across cancer types: digestive (n=95; 10.93%), urinary (n=84; 9.67%), respiratory (n=77; 8.86%), 
skin (n=90; 10.36%) and leukemia (n=83; 9.55%) (chi-square = 35.1004, df=14, P=0.0014). 
The information on body mass index (BMI) is missing for 36 individuals and the cohort while 
classified according to the National Institute of Health, National Heart, Lung and Blood Institute 
(NHLBI) BMI index (Kushner, 2018), majority (n=283; 32.57%) of the individuals are obese and 
the distribution is statistically different compared to normal weight (n=238; 27.38%), overweight 
(n=240; 27.62%) and extremely obese (n=72; 8.29%). While the frequencies across cancer types 
varied from overall cancer, major proportion of individuals with normal weight in digestive (n=49; 
5.64%), obese in urinary (n=41; 4.72%) / leukemia (n=33; 3.80%) and overweight in respiratory 
(n=32; 3.68%) / skin (n=33; 3.80%) (chi-square = 54.2503, df=28, P=0.0021). 
In contrast, when the BMI considered as a continuous variable there was no statistical difference 
observed among the cancer groups, the median BMI among cancer groups are: digestive 27 (IQR 
23.09, 31.87), urinary 28 (25.29, 33.82), respiratory 27 (23.39, 31.84), skin 27 (24.19, 31.63) and 
leukemia 28 (24.56, 31.7)  (Kruskal Wallis = 10.4428, df=7, P=0.1648). 
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There are no statistical differences in patients with anemia (chi-square = 5.8739, df=7, P=0.5545), 
depression (chi-square = 2.0595, df=7, P=0.9582), diabetes (chi-square = 10.462, df=7, P=0.1639), 
GERD (chi-square = 7.2363, df=7, P=0.4047), heart failure (chi-square = 4.1677, df=7, P=0.7603), 
hypertension (chi-square = 13.4567, df=7, P=0.0617) and hyperlipidemia (chi-square = 11.4824, 
df=7, P=0.1189) across different cancer groups.  
To estimate the impact of kidney function to cause cancer, estimated Glomerular Filtration Rate is 
used as a surrogate, but there are no statistical differences between estimated glomerular filtration 
rate groups and cancer. A major proportion of the cancer incidents were noticed in patients with 
mild/mild to moderate kidney dysfunction (n=553; 63.63%) compared to individuals with 
moderate / severe kidney problem (n= 316; 36.36%) (Chi-Square = 15.4484, df=21, P=0.7998).  
The median estimated Glomerular Filtration Rate did not have statistical differences among cancer 
types: digestive 51 (IQR 36.66, 60), urinary 47 (37.66, 55.33), respiratory 53 (40, 60), skin 53 (44, 
60) and leukemia 52 (36.66, 60) (Kruskal Wallis = 9.4029, df=7, P=0.2250). The median estimated 
Glomerular Filtration Rate among all the cancer types could be classified as KDIGO G3a stage 
mild to moderate kidney dysfunction (Bargman & Skorecki, 2018).  
There were statistically significant differences in the median age with change in clinical kidney 
function: severe dysfunction (65, IQR: 59.42, 75.38), moderate to severe dysfunction (77, IQR: 
67.84, 82.85), mild to moderate dysfunction (72, IQR: 64.72, 80.65) and mild dysfunction (70, 
IQR: 61.69, 76.81) (Kruskal Wallis = 38.99, df=3, P < 0.001). The distribution of subjects based 
on kidney function among age groups was statistically different (Chi-Square= 32.72, df=9, P < 
0.001). Among the individuals with severe kidney dysfunction, majority of the subjects were 
within the age group of 60 – 60 years (n=44; 5.06%) and the age groups 70 – 79 years was higher 
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among moderate to severe dysfunction (n=65; 7.48%), mild to moderate dysfunction (n=98; 
11.28%) and mild dysfunction (n=80; 9.21%). 
The subject’s gender (Chi-Square=6.48, df=3, P = 0.09) and BMI (Chi-Square=14.89, df=12, P = 
0.2473) do not have statistical differences among individuals with changes in kidney function. The 
median BMI among individuals with change in kidney function did not have statistical differences 
(Kruskal-Wallis= 1.3054, df=3, P = 0.7279). The median BMI in severe dysfunction is 27 (IQR: 
22.93, 33.03), moderate to severe dysfunction 27 (IQR: 23.94, 33.36), mild to moderate 
dysfunction 28 (IQR: 24.27. 34.11) and mild dysfunction 28 (IQR: 23.81, 32.45). According to 
the NHLBI BMI scale based on the median BMI, all the subjects could be classified as overweight 
(Kushner, 2018). The ethnic group being Caucasians (n=702; 80.78%) was predominant in the 
cohort and even across different kidney function categories: severe dysfunction (n=91; 10.47%), 
severe to moderate dysfunction (n=153; 17.61%), mild to moderate dysfunction (n=262; 30.15%) 
and mild dysfunction (n=196; 22.55%) which was statistically different compared to the other 
ethnicities (Chi-Square= 16.98, df=6, P = 0.0093).  
The chronic medical conditions anemia (Chi-Square= 22.3259, df=3, P < 0.001) and GERD (Chi-
Square= 8.1441, df=3, P = 0.0431) are statistical different among kidney function groups. The 
spread of anemia across individuals with mild to moderate dysfunction with a higher proportion 
(n=137; 15.77%) and followed by moderate to severe dysfunction (n=94; 10.82%), mild 
dysfunction (n=84; 9.67%), severe dysfunction (n=76; 8.75%). The GERD condition among mild 
to moderate dysfunction (n=103; 11.85%) is higher and mild dysfunction (n=60; 6.9%), moderate 
to severe dysfunction (n=41; 4.72%) and severe dysfunction (n=38; 4.37%).  
The remaining chronic conditions did not differ with change in kidney function: depression (Chi-
Square= 0.3931, df=3, P = 0.9417), diabetes (Chi-Square= 3.9309, df=3, P = 0.269), heart failure 
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(Chi-Square= 3.8074, df=3, P = 0.3607), hypertension (Chi-Square= 4.0886, df=3, P = 0.521) and 
hyperlipidemia (Chi-Square= 1.5287, df=3, P = 0.6757).  
The median time in weeks to develop cancer among individuals with a change in kidney function 
was not statistically different (Kruskal-Wallis= 0.0969, df=3, P = 0.9922). The median duration in 
weeks to develop cancer is narrow among individuals with severe dysfunction (45, IQR: 3.85, 
175.28) and almost similar among moderate to severe dysfunction (49, IQR: 8.28, 164.28), mild 
to moderate dysfunction (48, IQR: 5.71, 137.71) and mild dysfunction (49, IQR: 3.21, 138.21).  
Additionally, active smoking or smoking history is a major confounding factor associated with 
cancer development; there are 17 (1.96%) individuals in the cohort.  
Discussion 
In the current study all the Chronic Kidney Disease patients who eventually developed cancer were 
included, taking into consideration that the individuals could be with the underlying impaired 
kidney function before clinically diagnosed as Chronic Kidney Disease.  
As hypothesized, the risk of cancer in Chronic Kidney Disease patients was high, and the age-
adjusted incidence rate among the cohort was exponentially higher, compared to the National (US), 
state (Nebraska) and city (Omaha-Council Bluffs region). The cancer incidence is predominant in 
elderly (median age 71 years; IQR: 63.53, 79.52) male (n=486; 55.93%) Caucasians (n=702; 
80.78%). The dominance in elderly could be due to the genetic changes due to aging, the changes 
in nuclear DNA could alter mutations, chromosomal aneuploidy, copy number variations and 
telomere shortening (Cabo & Couteur, 2018). In terms of gender, the alterations in genetics due to 
hormonal differences and molecular changes in male physiology could trigger cancer development 
(Kim, Lim, & Moon, 2018). Assuming that majority of the individuals receive care at Nebraska 
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Medicine from closer proximity, the ethnic variation could be due to the proportion of Caucasians 
(73.1%) in Omaha, NE (2010 Census Summary File 1, 2012).  
The cohort contains statistical differences in BMI groups, but the median BMI across different 
cancer groups did not flag some differences. This could be due to the classification of individuals 
with a borderline BMI into specific groups. Based on the median BMI among the frequent cancer 
types, the subjects could be classified as overweight. The reason behind overweight consistent 
among all the cancer types could be due to the reason that visceral adipose tissue which plays a 
crucial role in producing proinflammatory cytokines. The induction of inflammatory process 
activates nuclear factor Kappa B (NF-kB) and signal transducer and activation of transcription 3 
(STAT3). The NF-kB is a transcription factor has a potential to induce expression of protein 
structures associated with pro-inflammatory, proliferative and repetitive pathways (Jacob, 
Varghese, & Weil, 2018). 
The most frequent comorbidities in the cohort, anemia is related to the underlying Chronic Kidney 
Disease condition. In progressive Chronic Kidney Disease condition, the patients fail to produce 
erythropoietin and reduction in red blood cell survival usually progress to hypo-proliferative 
anemia, and it is associated with the clinical stage of Chronic Kidney Disease. The chance of a 
Chronic Kidney Disease patient to develop anemia would multiply in individuals with diabetes 
(Adamson, 2018). Similarly, the subjects in the cohort have statistical differences with a change 
in kidney function.  
Additionally, chronic medical conditions such as hypertension, hyperlipidemia, heart failure, and 
diabetes increase the risk of cancer incidence (Tu et al., 2018). The cardiovascular diseases alter 
hemodynamic and neurohormonal factors that trigger increased reactive oxygen species, altered 
cardiac gene expression, increases oxidative stress, myocyte necrosis and apoptosis (Helmut 
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Drexler, 2010). The collective factors increase mutagen sensitivity, DNA damage (Federici et al., 
2015). The patients with type 2 diabetes have increased production of reactive oxygen species, 
reduced antioxidant withhold capacity, and susceptible to DNA damage (Lee & Chan, 2015).  
The literature did not support evidence for a specific cancer type, and similarly, the results from 
the cohort did not have statistical differences of cardiovascular diseases or diabetes across cancer 
types.  
As tobacco smoking is a significant factor associated with cancer incidence, the electronic medical 
record information on tobacco smoking is documented for 17 individuals. I feel that the lower 
proportion of the smokers in the cohort could be due to under-reporting of medical information in 
the health records.  
Based on the literature, impaired kidney function is associated to cause oxidative stress due to 
Vitamin C deficiency, reduced Vitamin E, compromised glutathione system and increased pro-
oxidant activity due to aging, chronic inflammatory status. The oxidative stress and increased pro-
oxidant activity upon interaction with inflammatory stimuli, oxidant-free radicals are generated by 
phagocytic cells (Locatelli et al., 2003). The Chronic Kidney Disease patients often present with 
genomic instability, due to extensive genetic damage caused by a toxin and endogenous genotoxin 
accumulation (Rangel-Lopez et al., 2013). The genotoxic effect could lead to loss of chromosomal 
fragments or entire chromosomes, this could lead to the formation of micronuclei upon cell 
division. The cytokinesis-block micronucleus assay and comet assay revealed chromosomal 
abnormalities, reduced DNA repair and DNA lesions in Chronic Kidney Disease patients. But the 
population-based studies are inconsistent in stratifying the risk to a specific cancer type (Roth et 
al., 2008; Schupp et al., 2016).  
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The cancer incidence from the cohort did not have statistical differences among estimated 
Glomerular Kidney Function groups. Based on the median estimated Glomerular Filtration Rate 
among the cancer groups, the overall cohort could be classified as mild to moderate kidney 
dysfunction. 
Limitations: The study could not be generalized to a country-wide scale, as the samples are not 
randomly selected. Due to age group stratification which did not precisely match the age groups 
from the cancer database the incidence comparison group (US, Nebraska and Omaha-Council 
Bluffs region) is missing with the incidence information for the individuals of age 18 years.  
Recommendations for future projects:  
The current work is a preliminary analysis of the planned research. The study will be extended to 
identify the role of drug exposures, time to cancer analysis and estimating hazard proportion ratio 
among different cancer groups.  
 
Bibliography 
2010 Census Summary File 1. (SF1/10-4 (RV)). (2012). Washington: U.S. Census Bureau. 
Adamson, J. W. (2018). Iron Deficiency and Other Hypoproliferative Anemias. In J. L. Jameson, 
A. S. Fauci, D. L. Kasper, S. L. Hauser, D. L. Longo, & J. Loscalzo (Eds.), Harrison's 
Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education. 
Aykanat, B., Demircigil, G. C., Fidan, K., Buyan, N., Gulleroglu, K., Baskin, E., . . . Burgaz, S. 
(2011). Basal damage and oxidative DNA damage in children with chronic kidney disease 
measured by use of the comet assay. Mutation Research-Genetic Toxicology and 
Environmental Mutagenesis, 725(1-2), 22-28. doi:10.1016/j.mrgentox.2011.07.005 
23 
 
Bargman, J. M., & Skorecki, K. L. (2018). Chronic Kidney Disease. In J. L. Jameson, A. S. Fauci, 
D. L. Kasper, S. L. Hauser, D. L. Longo, & J. Loscalzo (Eds.), Harrison's Principles of 
Internal Medicine, 20e. New York, NY: McGraw-Hill Education. 
Bhattacharyya, S. (2015). Introduction to SNOMED CT: Springer. 
Burlew, M. (2005). SAS guide to report writing: examples: SAS Publishing. 
Cabo, R. d., & Couteur, D. G. L. (2018). The Biology of Aging. In J. L. Jameson, A. S. Fauci, D. 
L. Kasper, S. L. Hauser, D. L. Longo, & J. Loscalzo (Eds.), Harrison's Principles of 
Internal Medicine, 20e. New York, NY: McGraw-Hill Education. 
Chien, C. C., Han, M. M., Chiu, Y. H., Wang, J. J., Chu, C. C., Hung, C. Y., . . . Weng, S. F. 
(2017). Epidemiology of cancer in end-stage renal disease dialysis patients: a national 
cohort study in Taiwan. Journal of Cancer, 8(1), 9-18. doi:10.7150/jca.16550 
Christensson, A., Savage, C., Sjoberg, D. D., Cronin, A. M., O'Brien, M. F., Lowrance, W., . . . 
Lilja, H. (2013). Association of cancer with moderately impaired renal function at baseline 
in a large, representative, population-based cohort followed for up to 30 years. 
International Journal of Cancer, 133(6), 1452-1458. doi:10.1002/ijc.28144 
Cody, R. (2011). SAS statistics by example: SAS Institute. 
Control, C. f. D., & Prevention. (2008). United States Cancer Statistics: 1999–2005 Incidence, 
Wonder on-Line Database. Atlanta: United States Department of Health and Human 
Services, CDC, National Cancer Institute.  
Corredor, Z., Stoyanova, E., Rodriguez-Ribera, L., Coll, E., Silva, I., Diaz, J. M., . . . Pastor, S. 
(2015). Genomic Damage as a Biomarker of Chronic Kidney Disease Status. 
Environmental and Molecular Mutagenesis, 56(3), 301-312. doi:10.1002/em.21911 
24 
 
Federici, C., Drake, K. M., Rigelsky, C. M., McNelly, L. N., Meade, S. L., Comhair, S. A. A., . . . 
Aldred, M. A. (2015). Increased Mutagen Sensitivity and DNA Damage in Pulmonary 
Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 
192(2), 219-228. doi:10.1164/rccm.201411-2128OC 
Helmut Drexler, G. H. (2010). Physiology of the Normal and Failing Heart. In M. H. Crawford, 
MD; DiMarco, John P., MD, PhD; Paulus, Walter J., MD, PhD, FESC (Ed.), Cardiology 
(Third ed., pp. 923-938). Philadelphia, PA: Elsevier. 
Iff, S., Craig, J. C., Turner, R., Chapman, J. R., Wang, J. J., Mitchell, P., & Wong, G. (2014). 
Reduced Estimated GFR and Cancer Mortality. American Journal of Kidney Diseases, 
63(1), 23-30. doi:10.1053/j.ajkd.2013.07.008 
International Classification of Diseases for Oncology. (2013). In C. P. April Fritz, Andrew Jack, 
Kanagaratnam Shanmugaratnam, Leslie Sobin, D Max Parkin, Sharon Whelan (Ed.).  
Jacob, M., Varghese, J., & Weil, P. A. (2018). Cancer: An Overview. In V. W. Rodwell, D. A. 
Bender, K. M. Botham, P. J. Kennelly, & P. A. Weil (Eds.), Harper's Illustrated 
Biochemistry, 31e. New York, NY: McGraw-Hill Education. 
Kim, H.-I., Lim, H., & Moon, A. (2018). Sex Differences in Cancer: Epidemiology, Genetics and 
Therapy. Biomolecules & therapeutics, 26(4), 335-342. doi:10.4062/biomolther.2018.103 
Kushner, R. F. (2018). Evaluation and Management of Obesity. In J. L. Jameson, A. S. Fauci, D. 
L. Kasper, S. L. Hauser, D. L. Longo, & J. Loscalzo (Eds.), Harrison's Principles of 
Internal Medicine, 20e. New York, NY: McGraw-Hill Education. 
Lee, S. C., & Chan, J. (2015). Evidence for DNA Damage as a Biological Link Between Diabetes 
and Cancer. Chinese Medical Journal, 128(11), 1543-1548. doi:10.4103/0366-
6999.157693 
25 
 
Lin, H. F., Li, Y. H., Wang, C. H., Chou, C. L., Kuo, D. J., & Fang, T. C. (2012). Increased risk 
of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. 
Nephrology Dialysis Transplantation, 27(4), 1585-1590. doi:10.1093/ndt/gfr464 
Locatelli, F., Canaud, B., Eckardt, K. U., Stenvinkel, P., Wanner, C., & Zoccali, C. (2003). 
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. 
Nephrology Dialysis Transplantation, 18(7), 1272-1280. doi:10.1093/ndt/gfg074 
Lowrance, W. T., Ordonez, J., Udaltsova, N., Russo, P., & Go, A. S. (2014). CKD and the Risk of 
Incident Cancer. Journal of the American Society of Nephrology, 25(10), 2327-2334. 
doi:10.1681/asn.2013060604 
Maisonneuve, P., Agodoa, L., Gellert, R., Stewart, J. H., Buccianti, G., Lowenfels, A. B., . . . 
Boyle, P. (1999). Cancer in patients on dialysis for end-stage renal disease: an international 
collaborative study. The Lancet, 354(9173), 93-99. doi:10.1016/S0140-6736(99)06154-1 
Rangel-Lopez, A., Paniagua-Medina, M. E., Urban-Reyes, M., Cortes-Arredondo, M., Alvarez-
Aguilar, C., Lopez-Meza, J., . . . Paniagua, J. R. (2013). Genetic damage in patients with 
chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study. 
Mutagenesis, 28(2), 219-225. doi:10.1093/mutage/ges075 
Roth, J. M., Restani, R. G., Goncalves, T. T. S., Sphor, S. L. S., Ness, A. B., Martino-Roth, M. G., 
& Garcias, G. L. (2008). Genotoxicity evaluation in chronic renal patients undergoing 
hemodialysis and peritoneal dialysis, using the micronucleus test. Genetics and Molecular 
Research, 7(2), 433-443. doi:10.4238/vol7-2gmr441 
SAS 9.4. (2012). SAS Institue Inc., Cary, NC, USA.  
26 
 
Schupp, N., Stopper, H., & Heidland, A. (2016). DNA Damage in Chronic Kidney Disease: 
Evaluation of Clinical Biomarkers. Oxidative Medicine and Cellular Longevity, 10. 
doi:10.1155/2016/3592042 
Shebl, F. M., Warren, J. L., Eggers, P. W., & Engels, E. A. (2012). Cancer risk among elderly 
persons with end-stage renal disease: a population-based case-control study. Bmc 
Nephrology, 13, 8. doi:10.1186/1471-2369-13-65 
SNOMED, C. (2014). Starter Guide. IHTSDO. December.  
Tu, H., Wen, C. P., Tsai, S. P., Chow, W.-H., Wen, C., Ye, Y., . . . Wu, X. (2018). Cancer risk 
associated with chronic diseases and disease markers: prospective cohort study. BMJ, 360. 
doi:10.1136/bmj.k134 
Wong, G., Hayen, A., Chapman, J. R., Webster, A. C., Wang, J. J., Mitchell, P., & Craig, J. C. 
(2009). Association of CKD and Cancer Risk in Older People. Journal of the American 
Society of Nephrology, 20(6), 1341-1350. doi:10.1681/asn.2008090998 
Yoo, K. D., Lee, J. P., Lee, S. M., Park, J. Y., Lee, H., Kim, D. K., . . . Kim, Y. S. (2017). Cancer 
in Korean patients with end-stage renal disease: A 7-year follow-up. Plos One, 12(7), 15. 
doi:10.1371/journal.pone.0178649 
 
 
 
 
 
 
27 
 
Capstone Experience Reflection:  
• My capstone activity is a collaboration with Public Health Informatics Lab, UNMC DRC 
– II. At Public Health Informatics Lab, Dr. Campbell and team maintained a clinical data 
warehouse called i2b2 (Informatics for integrating Biology & the Bedside), based on the 
de-identified patient electronic medical records who received care services at Nebraska 
Medicine.  
• The organization is multi-disciplinary, combination of health care and data science experts 
to maintain and execute queries to develop evidence-based medicine insights. 
• The capstone opportunity is my first-hand experience to handle electronic health record 
information at a larger volume.  
• The tasks related to the capstone allowed me to gain detailed understanding on SNOMED 
CT coding and cross mapping to the ICD codes.  
• It’s an intense exercise for me to use SQL and data mining strategies.  
• The planned activity trained me to be a liaison between clinical and data science teams in 
parallel.  
• Additionally, I gained experience on critical thinking related to epidemiological and 
statistical application in real time research.  
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